A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

14209JANSSEN-70033093STR3001OpenA Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack70033093STR3001NCT05702034IndustrialAdultTreatmentOtherCarter Denny, MaryGeorgetown University Medical Center : Micah Hamilton; Lombardi Comprehensive Cancer Center : Micah HamiltonGUMC Neurology; GUMC PFS15852Micah HamiltonMicah Hamiltonmgh62@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>